Clinical Trial Update: Dalfampridine and Gait in Spinocerebellar Ataxias [NA]

View source ↗

Summary

A completed clinical trial evaluated dalfampridine for improving gait in spinocerebellar ataxias, including Types 1, 2, 3, and 6, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Ataxias Type 1
• Spinocerebellar Ataxias Type 2
• Spinocerebellar Ataxias Type 3
• Spinocerebellar Ataxias Type 6

Drugs mentioned

• Dalfampridine (dalfampridine)

Snippet

Sponsor: University of Florida | Conditions: Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2 | NA | Status: COMPLETED | Results posted: 2015-01-12